Larimar Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Larimar Therapeutics, Inc. (Nasdaq: LRMR) on January 22, 2025. The report details a corporate governance event involving the Compensation Committee and the Board of Directors regarding executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity-based compensation awards and does not contain financial statement data.
Material Changes
On January 22, 2025, the Company granted performance-based restricted stock units (PSUs) to four key officers. The awards are contingent upon the achievement of specific regulatory milestones:
- Carole S. Ben-Maimon, M.D. (CEO): 100,000 PSUs
- Michael Celano (CFO): 50,000 PSUs
- Gopi Shankar, Ph.D., MBA, FAAPS (Chief Development Officer): 25,000 PSUs
- Russell G. Clayton, DO (Chief Medical Officer): 25,000 PSUs
Vesting Schedule: Upon the Compensation Committee's determination that regulatory milestones are achieved (the "Achievement Determination Date"), 50% of the earned portion vests immediately. The remaining 50% vests on the one-year anniversary of that date.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, general outlook commentary, or specific risk factors beyond the inherent contingency of the PSU awards. The awards are subject to the terms of the Performance-Based Restricted Stock Unit Award Agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 to understand the specific regulatory milestones required to earn the PSUs.
- Verify the total number of shares authorized under the 2020 Equity Incentive Plan to assess dilution impact.
- Confirm the current stock price to estimate the potential value of the awards upon vesting.
- Monitor future filings for the "Achievement Determination Date" regarding the regulatory milestones.